These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 1512940)

  • 1. [Sputum penetration of levofloxacin and its clinical efficacy in patients with chronic lower respiratory tract infections].
    Nakamori Y; Tsuboi E; Narui K; Nakatani T; Nakata K; Sugi H
    Jpn J Antibiot; 1992 May; 45(5):539-47. PubMed ID: 1512940
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Laboratory and clinical studies on levofloxacin].
    Tanaka K; Iwamoto M; Maesaki S; Koga H; Kohno S; Hara K; Sugawara K; Kaku M; Kusano S; Sakito O
    Jpn J Antibiot; 1992 May; 45(5):548-56. PubMed ID: 1512941
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Levofloxacin concentrations in serum, sputum and lung tissue: evaluation of its efficacy according to breakpoint].
    Fujita A; Miya T; Tanaka R; Hirayama S; Isaka H; Ono Y; Koshiishi Y; Goya T
    Jpn J Antibiot; 1999 Nov; 52(11):661-6. PubMed ID: 10659442
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Chemotherapy of biliary tract infections (XXXVII). Excretion into bile and gallbladder tissue levels of levofloxacin and its clinical effect in biliary tract infections].
    Tanimura H; Ohnishi H; Okamura T; Uenishi M; Ichimiya G; Kobayashi Y; Aoki Y; Oka S; Yamamoto S; Shimada K
    Jpn J Antibiot; 1992 May; 45(5):557-68. PubMed ID: 1512942
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Levofloxacin: penetration into sputum and once-daily treatment of respiratory tract infections.
    Nakamori Y; Miyashita Y; Nakatani I; Nakata K
    Drugs; 1995; 49 Suppl 2():418-9. PubMed ID: 8549384
    [No Abstract]   [Full Text] [Related]  

  • 6. Clinical evaluation of oral levofloxacin 500 mg once-daily dosage for treatment of lower respiratory tract infections and urinary tract infections: a prospective multicenter study in China.
    Zhang YY; Huang HH; Ren ZY; Zheng HG; Yu YS; Lü XJ; Xiao ZK; Yang HF; Xiu QY; Chen BY; Yue HM; Hao QL; Huang JA; Ma H; Xiao W; Guo DY; Si B; Sun SH; Zhang W; Li QH; Shen HH; Duan J; Li HY; Yao WZ; Gu JM; Xia QM; Ying KJ; Liu A; Yang HP; Shi MH; Sun TY; Ding GH; Wu GM
    J Infect Chemother; 2009 Oct; 15(5):301-11. PubMed ID: 19856068
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Population pharmacokinetics of oral levofloxacin 500 mg once-daily dosage in community-acquired lower respiratory tract infections: results of a prospective multicenter study in China.
    Zhang J; Xu JF; Liu YB; Xiao ZK; Huang JA; Si B; Sun SH; Xia QM; Wu XJ; Cao GY; Shi YG; Zhang YY
    J Infect Chemother; 2009 Oct; 15(5):293-300. PubMed ID: 19856067
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Clinical pharmacology and efficacy of levofloxacin in elderly patients].
    Aoki N; Usuda Y; Koda Y; Takasawa T; Wakabayashi N; Hayashi S; Nitta I; Honma C; Watanabe K
    Jpn J Antibiot; 1992 May; 45(5):530-8. PubMed ID: 1512939
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Permeability and concentration of levofloxacin in epithelial lining fluid in patients with lower respiratory tract infections.
    Zhang J; Xie X; Zhou X; Chen YQ; Yu JC; Cao GY; Wu XJ; Shi YG; Zhang YY
    J Clin Pharmacol; 2010 Aug; 50(8):922-8. PubMed ID: 20035039
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Pharmacokinetic and clinical evaluation of levofloxacin in obstetrics and gynecology].
    Cho N; Araki H; Kimura T; Shimizu A; Ichikawa K; Fukunaga K; Kunii K
    Jpn J Antibiot; 1992 Mar; 45(3):270-84. PubMed ID: 1512924
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Clinical studies and sputum levels of ceftriaxone once daily administration in respiratory tract infection].
    Kuwabara M; Sasaki H; Fukuhara H; Arita H; Inamizu T; Sadamoto K; Kimura T; Yamane K; Shigemoto M; Kawamoto M
    Jpn J Antibiot; 1989 Apr; 42(4):921-9. PubMed ID: 2671426
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Levofloxacin in the field of dermatology].
    Kanzaki H; Torigoe R; Yamada T; Abe Y; Shimoe K; Akiyama H; Arata J; Umemura S; Katayama H; Nishihara O
    Jpn J Antibiot; 1992 May; 45(5):576-84. PubMed ID: 1512944
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Concentration of levofloxacin in cervical mucus and its clinical effects on cervicitis.
    Chimura T; Arai M; Onuma Y; Oda T; Kawagoe S; Kunii K; Saito T; Saito N; Sato F; Numazaki M; Matsuo M; Murayama K; Morizaki N
    Jpn J Antibiot; 1997 Nov; 50(11):871-7. PubMed ID: 9651605
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [A study on the concentrations of levofloxacin in the gallbladder tissue and bile of patients].
    Hukagawa H; Noga K
    Jpn J Antibiot; 1992 Mar; 45(3):253-7. PubMed ID: 1512921
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of a new quinolone, levofloxacin in patients with surgical infections.
    Morimoto K; Kinoshita H; Nakatani S; Sakai K; Fujimoto M; Ohno K; Ueda T; Ohmori K; Yamazaki O; Doi S
    Jpn J Antibiot; 1992 Mar; 45(3):258-64. PubMed ID: 1512922
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Acute nongonococcal epididymitis--pharmacological and therapeutic aspects of levofloxacin].
    Saito I; Suzuki A; Saiko Y; Yokozawa M; Ono K; Miyata K; Miyamura R; Hamaya O; Kaneko K; Yamamoto T
    Hinyokika Kiyo; 1992 May; 38(5):623-8. PubMed ID: 1609677
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Pharmacokinetics and clinical efficacy of ciprofloxacin in aged patients with chronic respiratory diseases].
    Teramoto S; Fukuchi Y; Nagase T; Orimo H
    Jpn J Antibiot; 1992 May; 45(5):507-11. PubMed ID: 1512936
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Penetration of levofloxacin in bile].
    Mizuno A; Suzuki T; Taniguchi M; Yura J; Shinagawa N; Ishikawa S; Mashita K; Suzui K; Ishikawa M; Ishihara H
    Jpn J Antibiot; 1992 May; 45(5):569-75. PubMed ID: 1512943
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Serum levels and sputum levels of cefmenoxime in respiratory tract infections].
    Matsumoto Y; Ninomaru S; Koshobu T; Ishikawa J; Nakatani S; Sasaki T
    Jpn J Antibiot; 1985 Jun; 38(6):1638-42. PubMed ID: 3862881
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Clinical evaluation of sulbactam/cefoperazone for lower respiratory tract infections. Correlation between the efficacy of sulbactam/cefoperazone and beta-lactamase].
    Koga H; Tomono K; Hirakata Y; Kohno S; Abe K; Kawamoto S; Kusano S; Tanaka K; Morikawa N; Sugiyama H; Katsumata T; Sasayama K; Shimoguchi K; Hashimoto A; Matsumoto Y; Inoue Y; Ishiguro M; Hori H; Mashimoto H; Dotsu Y; Tanaka H; Imamura Y; Kanda T; Hara K
    Jpn J Antibiot; 1996 Aug; 49(8):800-7. PubMed ID: 9053534
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.